Last updated: 17 February 2023 at 4:51pm EST

Dr. Richard T. Kenney Net Worth




The estimated Net Worth of Richard T Kenney is at least $40.8 Thousand dollars as of 9 June 2021. Dr Kenney owns over 15,000 units of Sonnet BioTherapeutics Inc stock worth over $40,765 and over the last 9 years he sold SONN stock worth over $0.

Dr Kenney SONN stock SEC Form 4 insiders trading

Dr has made over 2 trades of the Sonnet BioTherapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of SONN stock worth $23,100 on 9 June 2021.

The largest trade he's ever made was buying 15,000 units of Sonnet BioTherapeutics Inc stock on 9 June 2021 worth over $23,100. On average, Dr trades about 3,571 units every 3 days since 2015. As of 9 June 2021 he still owns at least 50,000 units of Sonnet BioTherapeutics Inc stock.

You can see the complete history of Dr Kenney stock trades at the bottom of the page.





Dr. Richard T. Kenney biography

Dr. Richard T. Kenney is the Chief Medical Officer at Sonnet BioTherapeutics Inc.



How old is Dr Kenney?

Dr Kenney is 62, he's been the Chief Medical Officer of Sonnet BioTherapeutics Inc since . There are 3 older and 3 younger executives at Sonnet BioTherapeutics Inc. The oldest executive at Sonnet BioTherapeutics Holdings Inc is Dr. John K. Cini Ph.D., 68, who is the Chief Scientific Officer & Co-Founder.

What's Dr Kenney's mailing address?

Richard's mailing address filed with the SEC is 1616 Eastlake Ave E #310, Seattle, WA 98102, USA.

Insiders trading at Sonnet BioTherapeutics Inc

Over the last 7 years, insiders at Sonnet BioTherapeutics Inc have traded over $53,380 worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth $290,512 . The most active insiders traders include Pankaj Mohan, Donald J. Griffith, and Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of $21,474. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth $12,739.



What does Sonnet BioTherapeutics Inc do?

sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies



What does Sonnet BioTherapeutics Inc's logo look like?

Sonnet BioTherapeutics Holdings Inc logo

Complete history of Dr Kenney stock trades at Sonnet BioTherapeutics Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
9 Jun 2021 Richard T Kenney
Chief Medical Officer
Buy 15,000 $1.54 $23,100
9 Jun 2021
50,000
19 May 2021 Richard T Kenney
Chief Medical Officer
Buy 10,000 $1.55 $15,500
19 May 2021
35,000


Sonnet BioTherapeutics Inc executives and stock owners

Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include: